This single-center retrospective study aimed to compare the efficacy and safety of basiliximab versus a single 3 mg/kg dose of anti-thymocyte globulin (r-ATG) induction therapy in pediatric kidney transplant recipients. The r-ATG induction therapy was associated with lower incidence of acute rejection and similar safety profile compared to basiliximab.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username